Tonix Pharmaceuticals Holding Corp (TNXP)

[Monksdream]

TNXP 10Q due 3/26

[Monksdream]

TNXP 10Q due 3/19

[fink]

I don't know man, but getting to phase 3 can burn through an A/S
Pharma plays are a time suck and all hinges on the FDA.
I like the price, O/S and treatment targets.

I'd love to see it dip below .30 gain
I'll think about a starter then.



https://finance.yahoo.com/news/tonix-drug-shown-relieve-pain-130000206.html

[Nextbigone]

TNXP = Lifestyle company with periodic pump & dump spike.. well coordinated with friendly broker house. Rince - Roll Back - Repeat.. you loose all your money staying in.. Management is getting fat at the expense of skinny bag holders who drink tonix poison coo-laid

[1hot toddy]

MARKET CAP 9 MIL AND GOT 30 MIL UP FRONT PLUS 114 MIL LATER. 144 MIL VS 9 MIL MARKET CAP

[1hot toddy]

43000 SHARE BUY. INSTITUTIONAL INVESTORS PAYING 55 CENTS . PRICE 37 CENTS

[Nextbigone]

Hope is not a strategy. Read today abortion news. It makes you want to vomit again & again

[Nextbigone]

Monster will take all your remaining pennies. This is going to 0

[Nextbigone]

Classic abortion! This is classic pump&dump shame designed & executed in cold blood by horrible management team. One look at company chart with history of roll backs said it all. Charts don’t lie - people do. Buyer be aware of to-nix scam!

[threebabiesbusy]

Today’s study news is great. I guess the offering announced…not so much.

[dancy]

big "D"

TNXP ouching

[1hot toddy]

we have been waiting for MONSTER NEWS. GOT TO BE NOW

[peezypowell]

What is happening today?? With TNXP?
Company get bought?

[dancy]

H

eeeeeeeeeeeeeeeeeeeeeeeee

[sleepthief]

11m loan secured 🧐

[renaissance1]

Is there any hope with this company? Or is it dead as a door nail?

[sleepthief]

Should see $1 today

[Nextbigone]

Tonix Pharmaceuticals Announces Issuance of EU Patent Covering Intranasal Potentiated Oxytocin (TNX-1900) for the Treatment of Pain

New patent expected to expire in 2036

Proof of concept data from Phase 2 study for prevention of migraine headache expected in early December 2023

CHATHAM, N.J., October 4, 2023 – Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP), a clinical-stage biopharmaceutical company, announced today that the European Patent Office (EPO) issued European Patent No. 3242676 to the Company on October 4, 2023. The patent, entitled “Magnesium-Containing Oxytocin Formulations and Methods of Use”, claims methods and compositions for treating pain, including migraine headaches, using intranasal magnesium-containing oxytocin formulations. This patent, excluding possible patent term extensions, is expected to provide Tonix with market exclusivity in the member states of the European Patent Office until 2036. The U.S. Patent and Trademark Office (USPTO) has previously issued U.S. Patents No. 9,629,894 and 11,389,473 which are expected to provide market exclusivity in the U.S. until 2036.

In August 2023, Tonix announced it completed enrollment in its proof-of-concept Phase 2 PREVENTION study of TNX-1900 (intranasal potentiated oxytocin) for the prevention of migraine headache in chronic migraineurs with a total of 88 patients enrolled. The Company expects topline results from this trial in early December 2023.

“We believe this European patent combined with the U.S. issuance provides a strong patent position for TNX-1900 as we move forward in clinical development for the treatment of chronic migraine,” said Seth Lederman, M.D., Chief Executive Officer of Tonix Pharmaceuticals. “With a differentiated formulation including magnesium, which Tonix has shown to potentiate the action of oxytocin at oxytocin receptors in animal models, we believe TNX-1900 has the potential to help those chronic migraine sufferers by engaging and stimulating oxytocin receptors in the trigeminal ganglia. By expanding our patent coverage in Europe, we are ensuring the IP protection of this unique approach.”

In addition to Tonix’s patents that protect certain uses including treating migraine, Tonix has licensed patents from INSERM, the French national health and medical research institute, that claim methods of treating feeding disorders with onset during neonatal development, specifically Prader Willi syndrome and non-organic failure to thrive (NOFTT), using oxytocin (EP 2575853, US8853158 and US9125862) and licensed patents from University of Geneva that claim methods of treating insulin resistance using oxytocin (US9101569 and EP2571511).

About Migraine
Migraine is a neurological condition that manifests in throbbing headache, often on one side of the head, that lasts at least four hours. It can also be accompanied by nausea, vomiting, visual disturbances, and sensitivity to bright light, strong smells, and loud noises.1 Epidemiological studies indicate that globally, approximately 1.2 billion individuals suffer from migraines annually.2 In the U.S., approximately 39 million Americans suffer from migraines and among these individuals, approximately four million experience chronic migraines (15 or more headache days per month).2

[sc00pnDump]

8k out

[Nextbigone]

Another death spiral funding & share roll back to follow?

[Monksdream]

TNXP new 52 week low

[Monksdream]

TNXP new 52 week low

[Monksdream]

I agree
Four reverse splits since 2017
Burns cash out the ying yang
MO is it’s an enrichment scheme for four or five guys

[Nextbigone]

Looks like might drop to sub 0.50c
Doubt they can do roll back till next year..
real paper mill boys

[Monksdream]

TNXP new 52 week low

[Klinsmann]

In the end of that development I see a bottomed stock with a small float which can do a quick reversal...

[Nextbigone]

What’s the upside in reverse stock split? Meeting Nasdaq listing requirements?
Brokers sold 15% of float short prior to placement at higher prices and now dropped bid to .90c

[Klinsmann]

On watch for possible reversal

[Nextbigone]

Tonix stock Trades for less then cash value? Looks like brokers & shorts having hay day here

[Monksdream]

TNXP new 52 week low

[Nextbigone]

Tonix Pharmaceuticals Announces Pricing of $7 Million Public Offering


2023-07-27 21:31 ET - News Release

CHATHAM, N.J., July 27, 2023 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (“Tonix” or the “Company”), a biopharmaceutical company, today announced it has entered into a securities purchase agreement for the purchase and sale of 7,000,000 shares of its common stock (or common stock equivalents in lieu thereof) and warrants to purchase up to an aggregate of 7,000,000 shares of common stock in a public offering at a combined offering price of $1.00 per share (or common stock equivalents in lieu thereof) and accompanying warrant. The warrants have an exercise price of $1.00 per share, will become exercisable commencing the date of issuance, and will expire five years following the issuance date. The closing of the public offering is expected to take place on or about August 1, 2023, subject to the satisfaction of customary closing conditions.

The gross proceeds of the offering will be approximately $7 million before deducting placement agent fees and other estimated offering expenses payable by the Company. The Company intends to use the net proceeds from the offering for working capital and general corporate purposes, the build out of the Company’s manufacturing and research and development facilities, and the acquisition or licensing of approved products and products in development.

A.G.P./Alliance Global Partners is acting as lead placement agent for the offering.

Brookline Capital Markets, a division of Arcadia Securities, LLC is acting as co-placement agent for the offering.

This offering is being made pursuant to an effective shelf registration statement on Form S-3 (File No. 333-254975) previously filed with the U.S. Securities and Exchange Commission (the “SEC”). The offering will be made only by means of a prospectus supplement and accompanying base prospectus, as may be further supplemented by any free writing prospectus and/or pricing supplement that Tonix may file with the SEC. A preliminary prospectus supplement and accompanying prospectus describing the terms of the proposed offering have been filed with the SEC and are available on the SEC’s website located at http://www.sec.gov. Electronic copies of the final prospectus supplement may be obtained, when available, from A.G.P./Alliance Global Partners, 590 Madison Avenue, 28th Floor, New York, NY 10022, or by telephone at [phone], or by email at [e-mail]. Before investing in this offering, interested parties should read in their entirety the prospectus supplement and the accompanying prospectus and the other documents that Tonix has filed with the SEC that are incorporated by reference in such prospectus supplement and the accompanying prospectus, which provide more information about Tonix and such offering.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

Tonix Pharmaceuticals Holding Corp.*

Tonix is a biopharmaceutical company focused on commercializing, developing, discovering and licensing therapeutics to treat and prevent human disease and alleviate suffering. Tonix markets Zembrace® SymTouch® (sumatriptan injection) 3 mg and Tosymra® (sumatriptan nasal spray) 10 mg. Zembrace SymTouch and Tosymra are each indicated for the treatment of acute migraine with or without aura in adults. Tonix’s development portfolio is composed of central nervous system (CNS), rare disease, immunology and infectious disease product candidates. Tonix’s CNS development portfolio includes both small molecules and biologics to treat pain, neurologic, psychiatric and addiction conditions. Tonix’s lead CNS candidate, TNX-102 SL (cyclobenzaprine HCl sublingual tablet), is in mid-Phase 3 development for the management of fibromyalgia, nearing complete enrollment in a potentially registration-enabling study, with topline data expected in the fourth quarter of 2023. TNX-102 SL is also being developed to treat Long COVID, a chronic post-acute COVID-19 condition. Enrollment in a Phase 2 study has been completed, and topline results are expected in the third quarter of 2023. TNX-601 ER (tianeptine hemioxalate extended-release tablets), a once-daily formulation being developed as a treatment for major depressive disorder (MDD), is nearing complete enrollment with topline results expected in the fourth quarter of 2023. TNX-4300 (estianeptine) is a small molecule oral therapeutic in preclinical development to treat MDD, Alzheimer’s disease and Parkinson’s disease. TNX-1900 (intranasal potentiated oxytocin), in development for chronic migraine, is currently enrolling with topline data expected in the fourth quarter of 2023. TNX-1300 (cocaine esterase) is a biologic designed to treat cocaine intoxication and has been granted Breakthrough Therapy designation by the FDA. A Phase 2 study of TNX-1300 is expected to be initiated in the third quarter of 2023. Tonix’s rare disease development portfolio includes TNX-2900 (intranasal potentiated oxytocin) for the treatment of Prader-Willi syndrome. TNX-2900 has been granted Orphan Drug designation by the FDA. Tonix’s immunology development portfolio includes biologics to address organ transplant rejection, autoimmunity and cancer, including TNX-1500, which is a humanized monoclonal antibody targeting CD40-ligand (CD40L or CD154) being developed for the prevention of allograft rejection and for the treatment of autoimmune diseases. A Phase 1 study of TNX-1500 is expected to be initiated in the third quarter of 2023. Tonix’s infectious disease pipeline includes TNX-801, a vaccine in development to prevent smallpox and mpox. TNX-801 also serves as the live virus vaccine platform or recombinant pox vaccine platform for other infectious diseases. The infectious disease development portfolio also includes TNX-3900 and TNX-4000, classes of broad-spectrum small molecule oral antivirals.

* Tonix’s product development candidates are investigational new drugs or biologics and have not been approved for any indication.

Tonix Medicines has contracted to acquire the Zembrace SymTouch and Tosymra registered trademarks. Intravail is a registered trademark of Aegis Therapeutics, LLC, a wholly owned subsidiary of Neurelis, Inc.

[XWAVXALMIMAN]

Tonix had great news on 5/17 - huge potential
https://finance.yahoo.com/news/tonix-pharmaceuticals-announces-pharmacology-medicinal-110000260.html?guccounter=1&guce_referrer=aHR0cHM6Ly93d3cuZ29vZ2xlLmNvbS8&guce_referrer_sig=AQAAAE7tFxmE8Z0WjW38hWQgtZKT8v79B_38ZvR_gD7glijyZtdB_yPENydO6EF__62zQOyFK6xuP4s0RNkE92Zj5fVjJboGVuPneZljc3DLevnwL6wDUDVgYnziedxq-4-s4eV6x9-aVuHiP27Hgw2jSQlnRRmLRTzoNdvFyr0ifArG

Tianeptine is approved for depression and anxiety in Europe, Asia and South America. It works as well as other antidepressants without the side effects of sexual dysfunction and weight gain. It also may help Bipolar, Parkinson’s and Alzheimer’s.
Our CEO Lis presenting data at a conference this week. Stephen Stahl quoted in above article is one of the best Psychopharmacologists in the country.

I am a Psychiatrist attending the APA convention in SF. 2 other prominent Psychiatrists talked about Tianeptine today and one of them told me that he gets it from Europe for his patients.

My question is: if this drugs has been approved for many years in Europe and is generic, how can Tonix get a patent to sell it as a brand name drug?

[XWAVXALMIMAN]

I doubled down after the RS. Avoiding delisting with less shares outstanding, we are set up for a huge run on good news.

[Iron heart]

You nailed it!

The Repeated Big R/S will kick in here in the coming days/weeks...

[Value_Investor]

TNXP will crash back down to its most recent low $0.28 again very soon...

The Repeated Big R/S will kick in here in the coming days/weeks...

[Jayzp]

Ther meme stock ..good news

https://www.prnewswire.com/news-releases/theralink-acquires-exclusive-landmark-immunotherapy-patent-including-biomarker-from-vanderbilt-university-301787847.html

[AKATITUS]

Yep

[tradersam1]

Anyone watching this? Maybe a bottom has been reached? Thinking about jumpin in for the next pump

[Value_Investor]

You meant that the CEO will Rapidly Dilute the Endless New FREE shares Super-Heavily until TNXP hits a New Bottom $0.1?

It seems that we might see its Real Bottom $0.28 again in the coming days/weeks...

Anyway TNXP performs Very Similarly (5.6-Bagger rally) with its Bio-Med-Tech peer (PBH*: 5.2-Bagger rally) though its Top MV ($90,331,980.01) is Much Much Much Much Much Higher than the Top MV ($25,272,500.00) of its peer!

[waterchaser]

Did TNXP’s peer bleed 9% today?

[waterchaser]

What “peer”? Another heavily promoted scam?

[Value_Investor]

Do you know what kinds of the other Terrible things the CEO did to the company or stock beside the Endless Super Heavy Dilutions and Repeated Big R/S? Is he the only reason for TNXP to crash down to $0.1? I wish no more Big R/S in the future anyway! So far TNXP only crashed down to $0.28! So, it is still Long way to go before it hits $0.1...

At your-predicted Target $0.1 the MV of TNXP (5.4-Bagger) will be $5,753,629.30 which corresponding to the Same MV of its Very-Similar-performance peer (5.2-Bagger) at $0.00125215 v.s. at Mere $0.0002 now! At the Top $1.57 the MV of TNXP is $90,331,980.01 which corresponding to the Same MV of its peer at $0.01965876 which is 3.57432 Times of its Top $0.0055!

[waterchaser]

What biotech pink sheet “peer”?
TNXP is very similar to other stocks that trade on the scam OTC?

just like its Bio-Tech Pink-Sheet peer did Almost-the-Same performance

Peers? LOL.

[Value_Investor]

No doubt, those Super Stupid And Hyper Greedy TNXP-shorters were Super Painful with Hyper Losses when they saw TNXP soar 5.4-Bagger to $1.57 from the FAKE Bottom $0.289, just like its Bio-Tech Pink-Sheet peer did Almost-the-Same performance (5.2-Bagger Huge rally --- from its previous Bottom $0.0005 to its most recent high $0.0026)!

Anyway at the Top this stock has Eye-Popping high $90,331,980 MV based on Very Old OS count v.s. its peer only has Mere $25,272,500 MV at Top!

[waterchaser]

TNXP run should reverse soon as profit taking prevails.

[renaissance1]

wow. moving up and up and up.....

[AKATITUS]

Yep

[Value_Investor]

Wow, TNXP is heading onto the Same 5.2-Bagger Huge rally to hit $1.456 from its REAL Bottom $0.28 as its Bio-Tech Pink-Sheet peer (PBH*) did --- from previous Bottom $0.0005 to most recent high $0.0026!

[XWAVXALMIMAN]

TIZZUNI, good thing you got in before the TSUNAMI
Big up wave has just started

[TIZZUNI]

I was one of those stupid sellers but I bought back in today.